Hypertrophic Cardiomyopathy

CHICAGO — Good news for long-distance runners: The incidence of sudden cardiac arrest during marathons and half-marathons remained relatively stable over the past 2 decades, while the risk for sudden cardiac death markedly declined.

Danon disease is a rare but serious cardiomyopathy that drastically reduces life expectancy.

A structurally normal heart was the most common finding among athletes who experienced sudden cardiac death, but the cause and circumstance of death varied significantly by the athletes’ race, researchers reported.

A new guideline on hypertrophic cardiomyopathy endorses the use of cardiac myosin inhibitors for certain patients with obstructive HCM and encourages exercise in all patients with HCM.

Individuals with undiagnosed HF with preserved ejection fraction represent an at-risk group whose diagnosis could be improved by artificial intelligence trained with electronic health record data, according to researchers in the U.K.

Compared with placebo, aficamten was associated with increased exercise capacity and improvements in symptoms of obstructive hypertrophic cardiomyopathy, according to topline results of the phase 3 SEQUOIA-HCM trial.

PHILADELPHIA — The incidence of sudden cardiac death among National Collegiate Athletic Association athletes decreased over the past 2 decades, researchers reported at the American Heart Association Scientific Sessions.

Healio and Cardiology Today have compiled a list of the most-read cardiology news of October 2023.

Despite advances made for the treatment and management of hypertrophic cardiomyopathy, the condition remains a debilitating one for many patients, who are often undiagnosed until the disease has progressed.